Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4748392 | 1.00 | MME (0.44) | MMEACECPA1ACE2SLC22A6 | |
| SCHEMBL7378347 | 1.00 | MME (0.44) | MMEACECPA1ACE2SLC22A6 | |
| SCHEMBL13573121 | 0.84 | SLC22A6 (0.48) | SLC22A6SMN1; SMN2GPR84MAPTGABRR1 | |
| SCHEMBL29586601 | 0.82 | SLC22A6 (0.37) | MMEACECPA1ACE2SLC22A6 | |
| SCHEMBL26106950 | 0.82 | SLC22A6 (0.48) | MMEACECPA1ACE2SLC22A6 | |
| SCHEMBL14220059 | 0.82 | SLC22A6 (0.37) | MMEACECPA1ACE2SLC22A6 | |
| SCHEMBL1047606 | 0.82 | SLC22A6 (0.48) | MMEACECPA1ACE2SLC22A6 | |
| SCHEMBL9275230 | 0.82 | SLC22A6 (0.37) | MMEACECPA1ACE2SLC22A6 | |
| SCHEMBL4633347 | 0.81 | GPR84 (0.45) | SLC22A6SMN1; SMN2GPR84MAPTGABRR1 | |
| SCHEMBL10599123 | 0.81 | GPR84 (0.45) | SLC22A6SMN1; SMN2GPR84MAPTGABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3946229-B1 | MICROBIAL ENZYMES TO REDUCE MALODOUR OF SKIN AND TEXTILES | UNIV GENT (BE) | 2025-05-07 | — | — | EP | claimed |
| US-11787900-B2 | Biodegradable sustainable polyesters | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-10-17 | — | — | US | claimed |
| US-20230151142-A1 | BIODEGRADABLE SUSTAINABLE POLYESTERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-05-18 | — | — | US | claimed |
| WO-2023081515-A1 | BIODEGRADABLE SUSTAINABLE POLYESTERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-11 | — | — | WO | claimed |
| US-9957533-B2 | Mutant of propionyl-CoA transferase from Clostridium propionicum and preparing method for PLA or PLA copolymer using the same | LG CHEM, LTD. (KR) | 2018-05-01 | — | — | US | claimed |
| US-9920338-B2 | Recombinant Ralstonia eutropha capable of producing polylactic acid or polylatic acid polymer, and method for producing polylactic acid or polylatic acid copolymer using same | LG CHEM, LTD. (KR) | 2018-03-20 | — | — | US | claimed |
| EP-2089522-B1 | MUTANTS OF PHA SYNTHASE FROM PSEUDOMONAS SP.6-19 AND METHOD FOR PREPARING LACTATE HOMOPOLYMER OR COPOLYMER USING THE SAME | LG CHEMICAL LTD (KR) | 2017-11-01 | — | — | EP | claimed |
| EP-2650372-B1 | Preparation method of lactate polymers and lactate copolymers using polyhydroxyalkanoate synthase mutants | LG CHEMICAL LTD (KR) | 2017-03-01 | — | — | EP | claimed |
| US-20160312251-A1 | MUTANT OF PROPIONYL-COA TRANSFERASE FROM CLOSTRIDIUM PROPIONICUM AND PREPARING METHOD FOR PLA OR PLA COPOLYMER USING THE SAME | LG CHEM, LTD. (KR) | 2016-10-27 | — | — | US | claimed |
| US-9410167-B2 | Cells or plants producing polylactate or its copolymers and uses thereof | LG CHEM, LTD. (KR) | 2016-08-09 | — | — | US | claimed |
| EP-1036190-B1 | A METHOD FOR PRODUCING HYDROXYCARBOXYLIC ACIDS BY AUTO-DEGRADATION OF POLYHYDROXYALKANOATES | CHIROBIO INC (KR) | 2005-05-11 | — | — | EP | claimed |
| CN-1194098-C | Method for producing hydroxycarboxylic acids by auto-degradation of polyhydroxyalkanoates | KEROBIO LTD (KR) | 2005-03-23 | — | — | CN | claimed |
| US-20040152773-A1 | Fatty acid nutritional supplement | BAYLOR UNIVERSITY MEDICAL CENTER | 2004-08-05 | — | — | US | claimed |
| US-20040152776-A1 | Fatty acid treatment for cardiac patients | BAYLOR UNIVERSITY MEDICAL CENTER | 2004-08-05 | — | — | US | claimed |
| US-20030162833-A1 | Fatty acid treatment for cardiac patients | BAYLOR UNIVERSITY MEDICAL CENTER | 2003-08-28 | — | — | US | claimed |
| US-20030125386-A1 | Fatty acid nutritional supplement | BAYLOR UNIVERSITY MEDICAL CENTER | 2003-07-03 | — | — | US | claimed |
| US-6472188-B1 | SYNTHESIZING AND ACCUMULATING POLYHYDROXYALKANOATES (PHA) IN A CELL OF A MICROORGANISM BY CULTURING THE MICROORGANISM HAVING POLYHYDROXYALKANOATE DEPOLYMERASE ACTIVITY, COLLECTING CULTURED POLYMER, SUBJECTING TO MICROBIAL ENZYME DEGRADATION | CHIROBIO INC. (KR) | 2002-10-29 | — | — | US | claimed |
| CN-1301310-A | Method for producing hydroxycarboxylic acid by self-degradation of polyhydroxyalkanoate | KEROBIO LTD (KR) | 2001-06-27 | — | — | CN | claimed |
| EP-1036190-A1 | A METHOD FOR PRODUCING HYDROXYCARBOXYLIC ACIDS BY AUTO-DEGRADATION OF POLYHYDROXYALKANOATES | ChiroBio Inc. (KR) | 2000-09-20 | — | — | EP | claimed |
| WO-1999029889-A1 | A METHOD FOR PRODUCING HYDROXYCARBOXYLIC ACIDS BY AUTO-DEGRADATION OF POLYHYDROXYALKANOATES | LG CHEMICAL LTD. (KR) | 1999-06-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152776-A1 | Fatty acid treatment for cardiac patients | CPT1B, CPT2, CPT1A | MME 2591/4885ACE 2506/4885CPA1 1310/4885 |
| US-20030162833-A1 | Fatty acid treatment for cardiac patients | CPT1B, CPT2, CPT1A | MME 2591/4885ACE 2506/4885CPA1 1310/4885 |
| US-20040152773-A1 | Fatty acid nutritional supplement | FASN, SLC27A1, SLC27A2 | MME 4142/4885ACE 4451/4885CPA1 2449/4885 |
| US-20030125386-A1 | Fatty acid nutritional supplement | FASN, SLC27A1, SLC27A2 | MME 4142/4885ACE 4451/4885CPA1 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.